Business
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a
About this update from Replimune Group, Inc.
[{"type":"text","content":"WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 2-6, 2023. Replimune has one abstract selected for a poster discussion session that will include updated results from the first 75 patients treated with RP1 combined with nivolumab from the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial. In addition, the Company will also present data from the Phase 1 trial of RP2 combined with nivolumab in uveal melanoma, and trial-in-progress posters from the RP2/3 programs. Details for the presentations are as follows: Data Presentations Abstract Title: Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study Poster Session Title: Melanoma/Skin CancersPoster Session Date and Time: Saturday, June 3, 2023, 1:15 PM-4:15 PM CDTPoster Location: McCormick Place, Exhibit Hall A, Poster 272Abstract: 9509 The IGNYTE poster will be discussed as part of a poster discussion session focused on melanoma/skin cancers on Saturday, June 3, 2023 at 4:30 pm CDT in S406 at McCormick Place. Abstract Title: Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma Session Title: Melanoma/Skin CancersSession Date and Time: Saturday, June 3, 2023, 1:15 PM-4:15 PM CDTLocation: McCormick Place, Exhibit Hall A, Poster 290Abstract: 9527 Trial-in-progress presentations Abstract Title: A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck Session Title: Head and Neck CancerSession Date and Time: Monday, June 5, 2023,1:15 PM-4:15 PM CDTLocation: McCormick Place, Exhibit Hall A, Poster 95bAbstract: TPS6106 Abstract Title: An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanc...